Full-year sales for Roche’s diagnostics division were up by just 2% as the Big Pharma deals with ongoing challenges in China.  | Full-year sales for Roche’s diagnostics division were up by just 2% as ...

Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven ...

Roche reported 2025 sales of CHF 61.5 billion, driven by strong drug demand, rising profits, higher EPS, and a proposed ...

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...

With three new partnerships, 10x Genomics signals a move beyond research tools toward clinical diagnostics using its single-cell and spatial biology platforms.

The RNA analysis market is poised for significant growth due to rising demand in precision medicine, advancements in NGS technologies, and expanding use of RNA biomarkers in diagnostics and drug ...

The capital markets modernization we need starts not with the chain, but with the infrastructure that must eventually connect ...

Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related prod ...

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's ...

Group results In 2025, Roche achieved sales growth of 7% (2% in CHF) to CHF 61.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc ...

Epigenomics is at the forefront of biomedical innovation, offering unprecedented insights into the mechanisms that regulate ...

Ocado is adapting its advanced grocery fulfilment technology for pharmaceutical warehousing. Here's what it wants to achieve.